Another Alzheimer's Failure: Recapping INmune, Alzheimer's Space, and Refocus to Later-Stage Ideas
INmune Bio: Imminent Phase 2 Alzheimer's Readout of Unique Asset Presents Interesting Speculative Opportunity
Alpha Cognition: Launching Well-Differentiated Drug into a large Alzheimer's Market Opportunity
